Pharmacology and clinical experience with tiagabine

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 1, 2001, Pages 179-187

  Schachter, S C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Aminobutyric acid; Adjunctive therapy; Epilepsy; Monotherapy; Partial seizures; Review; Tiagabine; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 3A; DIAZEPAM; DIGOXIN; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; NIPECOTIC ACID; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; THEOPHYLLINE; TIAGABINE; TOLBUTAMIDE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; WARFARIN; ZOLPIDEM; ZONISAMIDE;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERANCE; FOCAL EPILEPSY; HEADACHE; HUMAN; INFANTILE SPASM; INFECTION; LIVER METABOLISM; LONG TERM CARE; MONOTHERAPY; MOUSE; NAUSEA; NERVOUSNESS; NONHUMAN; RAT; SOMNOLENCE; VERTIGO;

BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EPILEPSY; GABA AGONISTS; HUMANS; MULTICENTER STUDIES; NIPECOTIC ACIDS; RANDOMIZED CONTROLLED TRIALS;

EID: 0035023488     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.1.179     Document Type: Article

References (81)

1. Epilepsy: Frequency, causes and consequences
2. Women with epilepsy. Reproduction and effects of pregnancy on epilepsy
3. Pregnancy and epilepsy
4. A survey of epileptic disorders in southwest France: Seizures in elderly patients
5. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures
6. Update in the treatment of epilepsy
7. Treatment of seizures
8. Anti-epileptic drug therapy: General treatment principles and application for special patient populations
9. Options after the first anti-epileptic drug has failed
10. A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor
11. Anti-epileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy
12. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor
13. Blockade of GABA uptake with tiagabine inhibits audiogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat
14. Tiagabine
15. GABA uptake inhibitors: Relevance to anti-epileptic drug research
16. (R)-N-(4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl)nipecotic acid binds with high affinity to the brain GABA uptake carrier
17. Anticonvulsant action of tiagabine, a new GABA-uptake inhibitor
18. Basic mechanisms of Gabitril (tiagabine) and future potential developments
19. Tiagabine, SK&F 89976-A, CI-966 and NNC-711 are selective for the cloned GABA transporter GAT-1
20. The GABA transporter and its inhibitors
21. Tiagabine pharmacology in profile
22. Tiagabine
23. Absolute bioavailability of tiagabine
24. Effect of food on the bioavailability of tiagabine HC1
25. Role of the cytochrome P450 3A subfamily in the metabolism of (14C) tiagabine by human hepatic microsomes
26. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy
27. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function
28. Potential anti-epileptic drugs. Tiagabine
29. Pharmacokinetics and metabolism of (14C tiagabine) after oral administration to human subjects
30. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine
31. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses
32. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy
33. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures
34. Lack of clinically important drug interactions between tiagabine and carbamazepine, phenytoin, or valproate
35. Tiagabine, a novel anti-epileptic agent: Lack of pharmacokinetic interaction with digoxin
36. Tiagabine: Evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol
37. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin
38. Tiagabine monotherapy in the treatment of partial epilepsy
39. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers
40. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants
41. Tiagabine: Absence of kinetic or dynamic interactions with ethanol
42. Behavioral effects of GABA(A) receptor stimulation and GABA-transporter inhibition
43. Adjunctive treatment of partial seizures with tiagabine: A placebo-controlled trial
44. Summary of five controlled trials with tiagabine as adjunctive treatment of patients with partial seizures
45. International experience with tiagabine add-on therapy
46. Tiagabine for complex partial seizures: A randomized, add-on, dose- response trial
47. Tiagabine therapy for complex partial seizures
48. A double-blind, placebo-controlled trial of tiagabine given three- times daily as add-on therapy for refractory partial seizures
49. International experience with tiagabine add-on therapy
50. An overview of the efficacy and tolerability of new anti-epileptic drugs
51. Safety of tiagabine: Summary of 53 trials
52. Therapeutic choices and decisions
53. Status epilepticus and tiagabine therapy: Review of safety data and epidemiologic comparisons
54. Lack of aggravation of epilepsy by tiagabine
55. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy
56. Adjunctive tiagabine compared to phenytoin and carbamazepine in the multicenter, double-blind trial of complex partial seizures
57. A cost-effectiveness analysis of tiagabine, phenytoin and carbamazepine adjunctive therapy for patients with complex partial seizures
58. Long-term use of tiagabine for partial seizures
59. Reduction in concomitant AED use with tiagabine in a long-term clinical study
60. Adverse events with long-term tiagabine therapy
61. The incidence and prevalence of common adverse events in a long-term trial of tiagabine (Gabitril®, TGB)
62. Tiagabine: The safety landscape
63. Absence of visual field defects in patients taking tiagabine
64. Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures
65. A monotherapy approach with tiagabine
66. Effects of tiagabine monotherapy on abilities, adjustment and mood
67. Long term use of Gabitril® (tiagabine HC1) monotherapy in pediatric patients
68. Tiagabine in the treatment of infantile spasms
69. Efficacy and tolerability of tiagabine in infantile spasms
70. Tiagabine monotherapy in chronic partial epilepsy
71. Lack of visual field defects with long-term use of tiagabine
72. Cognitive effects of initial tiagabine monotherapy
73. Possible drug-induced thrombocytopenia secondary to tiagabine
74. Clinical and EEG findings in complex partial status epilepticus with tiagabine
75. Tiagabine-induced absence status in idiopathic generalized epilepsy
76. Two cases of non-convulsive status epilepticus in association with tiagabine therapy
77. Non-convulsive status epilepticus in two patients receiving tiagabine treatment
78. Tiagabine-related stupor: Evidence for a non-epileptic origin
79. Pregnancy and tiagabine exposure
80. High performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection
81. Tiagabine: Current status and potential clinical applications